Investors may find better financial performance in Royalty Pharma plc (RPRX)

At the time of writing, Royalty Pharma plc [RPRX] stock is trading at $35.10, up 0.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RPRX shares have gain 5.12% over the last week, with a monthly amount glided 5.98%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Royalty Pharma plc [NASDAQ: RPRX] stock has seen the most recent analyst activity on May 16, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $51. Previously, UBS downgraded its rating to Neutral on June 03, 2024, and kept the price target unchanged to $28. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $53 on May 13, 2022. Goldman initiated its recommendation with a Buy and recommended $56 as its price target on April 27, 2022. JP Morgan upgraded its rating to Overweight for this stock on April 14, 2022, but kept the price target unchanged to $50.

For the past year, the stock price of Royalty Pharma plc fluctuated between $24.05 and $35.38. Currently, Wall Street analysts expect the stock to reach $43.33 within the next 12 months. Royalty Pharma plc [NASDAQ: RPRX] shares were valued at $35.10 at the most recent close of the market. An investor can expect a potential return of 23.45% based on the average RPRX price forecast.

Analyzing the RPRX fundamentals

According to Royalty Pharma plc [NASDAQ:RPRX], the company’s sales were 2.26B for trailing twelve months, which represents an 0.05% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.84%, Pretax Profit Margin comes in at 0.78%, and Net Profit Margin reading is 0.48%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.16 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.14.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.74 points at the first support level, and at 34.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.31, and for the 2nd resistance point, it is at 35.51.

Ratios To Look Out For

It is important to note that Royalty Pharma plc [NASDAQ:RPRX] has a current ratio of 1.56. Further, the Quick Ratio stands at 1.56, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 8.72, the price to book ratio is 2.23 and price to earnings (TTM) ratio is 14.31.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.